Company: IMCR
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001671927-25-000006
Chunk: 18

Company: Immunocore Holdings plc
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 18
---
 our audit provides a reasonable basis for our opinion.

/s/ KPMG LLPWe served as the Company’s auditor from 2009 to 2023.London, United KingdomFebruary 28, 2024, except for Note 13, as to which the date is February 26, 2025.

F-4

Table of Contents

Immunocore Holdings Plc

Consolidated Balance Sheets

(in thousands, except share and per share data)

December 31,2024December 31,2023AssetsCurrent assetsCash and cash equivalents$455,731 $442,626 Marketable securities364,645 — Accounts receivable, net63,009 52,093 Prepaid expenses and other current assets41,033 29,600 Inventory, net5,446 4,501 Total current assets929,864 528,820 Property and equipment, net10,092 9,215 Operating lease right of use assets, net37,643 33,520 Deferred tax assets, net14,790 10,973 Other non-current assets17,117 14,473 Total assets$1,009,506 $597,001 Liabilities and shareholders’ equity  Current liabilities  Accounts payable$25,100 $17,798 Accrued expenses and other current liabilities185,534 119,835 Operating lease liabilities, current1,547 1,388 Total current liabilities212,181 139,021 Deferred revenue, non-current5,434 5,515 Operating lease liabilities, non-current40,162 35,611 Interest-bearing loans and borrowings391,013 48,011 Total liabilities648,790 228,158 Commitments and contingencies (Note 14)Shareholders’ equityOrdinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £97,454 and £109,355 shares as of December 31, 2024 and 2023, respectively, and 50,064,860 and 49,725,649 shares issued and outstanding as of December 31, 2024 and 2023, respectively.135 134 Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of December 31, 2024 and 2023.